NTRB
Price
$9.11
Change
-$0.80 (-8.07%)
Updated
Jul 7, 11:29 AM (EDT)
Capitalization
110.3M
86 days until earnings call
RARE
Price
$39.40
Change
-$0.51 (-1.28%)
Updated
Jul 7, 12:44 PM (EDT)
Capitalization
3.77B
24 days until earnings call
Interact to see
Advertisement

NTRB vs RARE

Header iconNTRB vs RARE Comparison
Open Charts NTRB vs RAREBanner chart's image
Nutriband
Price$9.11
Change-$0.80 (-8.07%)
Volume$128
Capitalization110.3M
Ultragenyx Pharmaceutical
Price$39.40
Change-$0.51 (-1.28%)
Volume$100
Capitalization3.77B
NTRB vs RARE Comparison Chart in %
Loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTRB vs. RARE commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Buy and RARE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (NTRB: $9.91 vs. RARE: $39.91)
Brand notoriety: NTRB and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 169% vs. RARE: 65%
Market capitalization -- NTRB: $110.3M vs. RARE: $3.77B
NTRB [@Biotechnology] is valued at $110.3M. RARE’s [@Biotechnology] market capitalization is $3.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTRB and RARE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 3 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • NTRB’s TA Score: 3 bullish, 4 bearish.
  • RARE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RARE is a better buy in the short-term than NTRB.

Price Growth

NTRB (@Biotechnology) experienced а +26.56% price change this week, while RARE (@Biotechnology) price change was +7.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.51%. For the same industry, the average monthly price growth was +14.00%, and the average quarterly price growth was -0.49%.

Reported Earning Dates

NTRB is expected to report earnings on Oct 01, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+5.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.77B) has a higher market cap than NTRB($110M). NTRB YTD gains are higher at: 110.403 vs. RARE (-5.134). NTRB has higher annual earnings (EBITDA): -9.68M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. NTRB (2.96M). NTRB has less debt than RARE: NTRB (282K) vs RARE (38.3M). RARE has higher revenues than NTRB: RARE (591M) vs NTRB (2.4M).
NTRBRARENTRB / RARE
Capitalization110M3.77B3%
EBITDA-9.68M-449.9M2%
Gain YTD110.403-5.134-2,150%
P/E RatioN/AN/A-
Revenue2.4M591M0%
Total Cash2.96M494M1%
Total Debt282K38.3M1%
FUNDAMENTALS RATINGS
NTRB vs RARE: Fundamental Ratings
NTRB
RARE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3649
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRB's Valuation (78) in the null industry is in the same range as RARE (80) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RARE’s over the last 12 months.

NTRB's Profit vs Risk Rating (94) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RARE’s over the last 12 months.

NTRB's SMR Rating (98) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RARE’s over the last 12 months.

NTRB's Price Growth Rating (36) in the null industry is in the same range as RARE (49) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RARE’s over the last 12 months.

NTRB's P/E Growth Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBRARE
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
77%
Momentum
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 5 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 5 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
72%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 27 days ago
88%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
78%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CWYUF18.930.11
+0.57%
SmartCentres Real Estate Investment Trust
FFDF35.00N/A
N/A
FFD Financial Corp.
JDEPF27.75N/A
N/A
JDE Peet's NV
FMCCM18.25N/A
N/A
Freddie Mac
MCEM237.00-0.98
-0.41%
Monarch Cement Co. (The)

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and SONN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and SONN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-7.56%
SONN - NTRB
29%
Poorly correlated
-5.54%
RARE - NTRB
27%
Poorly correlated
+1.14%
REPL - NTRB
27%
Poorly correlated
-1.57%
STOK - NTRB
27%
Poorly correlated
-0.61%
DNLI - NTRB
25%
Poorly correlated
-1.41%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+1.14%
CRNX - RARE
52%
Loosely correlated
+1.22%
DNLI - RARE
51%
Loosely correlated
-1.41%
NRIX - RARE
50%
Loosely correlated
+2.33%
COGT - RARE
50%
Loosely correlated
+2.29%
RVMD - RARE
50%
Loosely correlated
+1.83%
More